SOLIGENIX, INC. Payments for Repurchase of Initial Public Offering
SOLIGENIX, INC. (SNGX) reported Payments for Repurchase of Initial Public Offering of $192.13 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2019-11-12
- 2018-09-30: Payments for Repurchase of Initial Public Offering 9 month $192.13K.
- 2017-09-30: Payments for Repurchase of Initial Public Offering 9 month $146.88K.
| Period end | Payments for Repurchase of Initial Public Offering 9 month |
|---|---|
| 2018-09-30 | $192.13K 10-Q · filed 2019-11-12 |
| 2017-09-30 | $146.88K 10-Q · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |